Stock Analiz

Ginkgo Bioworks Holdings, Inc. DNA

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$9.61Market cap $623M
Open the interactive analysis →

Ginkgo Bioworks Holdings, Inc. (DNA) is a healthcare company listed in the US with a market value of about $623M. In the twelve months to September 30, 2026 it had revenue of $131M and net income of -$251M, a net margin of -192.0%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 17% a year, a 5-year average ROIC of -71%.

About Ginkgo Bioworks

Ginkgo Bioworks is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $54M in 2019 to $170M in 2025, growth of about 21.0% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 32% over three years (dilution for shareholders). It spends 143% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S4.8
P/B1.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-27.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-25.1%
Revenue growth (5 yrs, per year)17.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-360.7%
ROIC (5-yr avg.)-71.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$131M$170M$227M$251M$478M$314M$77M$54M
Net income-$251M-$313M-$547M-$893M-$2.1B-$1.8B-$127M-$119M
Free cash flow-$174M-$179M-$382M-$336M-$304M-$310M-$194M-$67M
EPS (diluted)$-4.17$-5.64$-10.54$-18.37$-50.20$-55.60$-4.00$-4.00
Net margin-192.0%-183.8%-240.9%-355.1%-440.6%-583.1%-165.2%-220.2%
ROIC—-33.1%-47.3%-64.6%-100.7%-109.3%-23.5%-11.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $8.00, 17% below the current price; targets range from $5.00 to $11.00; the consensus rating is “Underperform”; expected EPS is $-3.20 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Ginkgo Bioworks pay a dividend?

Not currently.

Is Ginkgo Bioworks a good stock to buy?

We do not give buy or sell advice. Ginkgo Bioworks scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.